BBNX — Q2 2026 Financial Report Analysis

Beta Bionics, maker of the iLet "bionic pancreas" — an insulin pump for people with type 1 diabetes that works out every insulin dose on its own from continuous glucose monitor readings — grew second-quarter 2026 net sales 38% to $32.0 million. Nearly all of that growth came from the disposable supplies existing users reorder, not from new pumps, and from the shift of patients into the pharmacy channel. Gross margin climbed to 59.0% from 53.8%, but a 58% jump in sales and marketing spending widened the net loss to $23.4 million from $16.9 million. Since the quarter closed, the company has cut its full-year revenue guidance by $10 million and raised about $150 million in new stock.

At a glance

• Supplies revenue roughly doubled to $19.1 million (+99%) while pump revenue slipped 5% to $12.9 million. Supplies (the single-use products used with the pump) are now 60% of sales, up from 41% — revenue that recurs every month a patient stays on the device.
• Gross margin of 59.0% (+5.2 points). Each dollar of sales now leaves 59 cents after the cost of making the product, helped by larger production runs, lower warranty costs and better spreading of factory overhead, per the 10-Q.
• Loss from operations was 80% of sales ($25.6 million). That is better than 86% a year ago, but the dollar loss grew by $5.7 million because the company is still spending faster than gross profit is growing.

The numbers

Six-month figures tell the same story: net sales of $59.6 million (+45.9%), gross margin of 59.3% (52.5% a year earlier) and a net loss of $45.3 million, almost unchanged from $45.5 million. Sequentially, Q2 sales were up 15.9% from Q1's $27.6 million, which the company describes as a seasonally weaker quarter. Management said new patient starts rose by at least 10% but less than 20% from Q1, and 69% of new users came from multiple daily injections (insulin pens or syringes) rather than switching from another pump.

Two sales channels, and why pump revenue is shrinking

The company sells through two routes. In the DME (durable medical equipment) channel, the patient's medical insurance pays for the pump up front and supplies separately. In the pharmacy benefit (PBP) channel, patients get the system through their pharmacy coverage. The channel table shows how different the economics are: in Q2, pharmacy-channel pump revenue was just $0.2 million against $11.4 million of pharmacy-channel supply revenue. So in that channel, revenue arrives as a stream of supply purchases over time rather than as a one-off pump sale.

The pharmacy channel is taking a larger share. It produced 36% of Q2 net sales (20% a year earlier), and pharmacy coverage accounted for a share of new patient starts in the "high 30s" percent, up from the "high 20s" in Q2 2025. The 10-Q attributes this to "expanded pharmacy benefit coverage enabled through contracts with PBMs and their affiliated health plans" (PBMs are the pharmacy benefit managers that run drug coverage for insurers). This explains the most counterintuitive line in the table: total revenue grew 38% while pump revenue fell, even with more patients starting. Moving patients to the pharmacy channel trades upfront revenue now for recurring revenue later. That makes near-term growth look slower than patient growth, but over a patient's lifetime it can produce at least as much revenue.

Margins improve, losses still grow

Gross profit rose $6.4 million to $18.9 million. The 10-Q credits the margin gain to "increased production scale, lower warranty expense and improved cost absorption". Margin has been around 59% since Q4 2025, so the year-over-year gain is real but has flattened in the last three quarters.

Below gross profit, total operating expenses grew 37.4% to $44.5 million, about the same pace as sales, so operating leverage (expenses growing more slowly than revenue) was modest. The biggest increase was in sales and marketing, up $9.0 million. Of that, $6.0 million was payroll for a larger sales force and customer-care team "in connection with the expansion of our sales territories". Research and development rose 15% to $10.2 million, and general and administrative costs rose 22% to $9.6 million. The net loss also widened because interest income fell to $2.2 million from $3.0 million as the cash pile from the January 2025 IPO shrinks.

What the headline numbers hide

• Adjusted EBITDA flatters mainly through stock pay. The company's adjusted EBITDA loss of $17.7 million is $5.7 million smaller than the GAAP net loss. The largest add-back is $7.0 million of stock-based compensation, up from $4.8 million a year ago. This is a real cost to shareholders (it is paid in new shares) even though no cash leaves the business. Interest income works the other way: it is subtracted, which makes adjusted EBITDA worse than net loss on that line. Only $0.2 million of genuinely one-off items (litigation and FDA-related quality remediation) were excluded this quarter.
• The flat first-half loss is a comparison effect. The H1 2026 net loss ($45.3 million) looks no worse than H1 2025 ($45.5 million). But the 2025 figure included a $12.5 million non-cash warrant revaluation charge tied to the IPO. Without it, the H1 loss widened by about $12 million.
• Cash burn is about $20 million a quarter. Operating activities used $38.5 million in the first half (versus $33.6 million a year earlier), and capital spending added another $2.4 million. Cash and investments fell from $264.6 million at year-end to $225.2 million. Before the September raise, the 10-Q said existing resources would fund the plan "through the first half of 2028".
• Working capital looks controlled. Since December 31, receivables rose 5% to $18.1 million and inventory rose 10% to $23.9 million, while the six months' sales were 46% above the prior-year period. Neither is outpacing the business.
• An open regulatory issue. In January 2026 the FDA issued a Warning Letter after a mid-2025 inspection of the Irvine facility, citing non-conformities in the quality management system, medical device reporting and corrections and removals. The company says it has responded and is still addressing the observations. Remediation costs are small so far ($0.6 million in H1), but the letter remains open.

Takeaway: Beta Bionics is turning into a supplies business. Supplies doubled while pump revenue shrank, and the move to the pharmacy channel pushes revenue later even as patient starts grow. Margins are already near 59%, so the question is no longer whether the product can make money per unit. It is whether operating spending, now growing as fast as sales, can level off before the cash runs out. The September stock sale made that runway much longer.

Since the quarter: Mint clearance, guidance cut and a $150 million raise

• Patch pump cleared. On September 14 the company announced FDA clearance of Mint, its tubeless patch pump. It brought full U.S. launch forward to Q1 2027 (it had said by the end of Q2 2027 in July) and targets capacity of at least 1.5 million disposable Mint units in 2027. Mint will launch only through the pharmacy channel. A next-generation dosing algorithm ("3D Intelligence") has been submitted to the FDA, and the company hopes to launch it on the iLet by the end of 2026.
• 2026 revenue guidance cut to $121–126 million from $131–136 million. The company says this reflects "a potential revenue deferral impact of up to $10 million in the fourth quarter of 2026 as new prospective iLet users could choose to await the launch of Mint", and expects Mint to win that revenue back in 2027. Gross margin guidance of 58.5%–59.5% was kept, as was the 37%–39% pharmacy share of new patient starts. The company expects Mint to reduce 2027 gross margin slightly.
• Equity raise. On September 15 the company priced 7.65 million shares plus pre-funded warrants for 1.04 million more at $17.25, for about $150 million in gross proceeds (before fees, and before an underwriter option for 1.3 million more shares). That adds roughly 19% to the 45.0 million shares outstanding at June 30, which spreads future earnings over more shares.

Outlook

With $59.6 million of sales in the first half, the new $121–126 million range implies about $61–66 million in the second half. That is only slightly above the first half, compared with the 46% growth just reported. That gap is the company's own estimate of how many buyers will wait for Mint. Q3 results (expected around late October to early November, based on the July 29 timing of Q2) are the first test. In our view, three things matter: whether new patient starts keep growing despite the Mint announcement, whether sales and marketing spending starts to grow more slowly than revenue, and whether the FDA Warning Letter is closed before Mint ships. The new cash removes near-term funding risk. Shareholders have paid for it with dilution, though, and the business remains far from breakeven, with operating losses equal to 80% of sales.